Key Highlights

  • Third quarter loss per share was USD 0.73 against an estimated USD 0.64 loss, with no Revenue reported.
  • Cash, equivalents and marketable securities were USD 413.8 million, which the company guided to fund its plan through mid-2028.
  • Topline results from the Phase 3 OPERA-01 trial of palazestrant are guided for the first quarter of 2027.
  • Nine-month net loss was USD 189.9 million, up from USD 116.4 million, and the accumulated Deficit was USD 787.4 million.

Olema Pharmaceuticals (NASDAQ:OLMA), a clinical-stage oncology company, reported a third quarter 2026 loss of USD 0.73 per share, wider than the USD 0.64 estimated loss. The company reported no revenue. Net loss for the nine months was USD 189.9 million, against USD 116.4 million a year earlier, and the accumulated deficit was USD 787.4 million.

General and administrative expenses for the nine months rose USD 13.9 million, or 99%, from the same period of 2025, which sits alongside a net loss that was up about 63% from USD 116.4 million. Costs incurred under its 2024 agreement with Novartis are recorded within Research and Development expenses.

Cash, Runway and Going Concern Language

Cash, cash equivalents and marketable securities were USD 413.8 million at September 30. The company states that this balance, together with the available balance under its Credit facility, funds its current operating plan through mid-2028. The filing also states that conditions raise substantial doubt about the company's ability to continue as a going concern over the long term. Outstanding pre-funded warrants totaled 13,594,149 shares across three issuances at an exercise price of USD 0.0001.

Palazestrant Development

Palazestrant is an oral small molecule that acts as both a complete estrogen receptor antagonist and a selective estrogen receptor degrader, being studied in recurrent, locally advanced or metastatic ER-positive, HER2-negative breast cancer. The company reports clinical studies across more than 400 patients showing anti-tumor activity, favorable tolerability and combinability with CDK4/6 inhibitors.

OPERA-01, a pivotal Phase 3 trial of palazestrant as monotherapy in second and third-line disease, began in November 2023. Enrollment is complete, topline results are guided for the first quarter of 2027, and the company plans to submit a New Drug Application in 2027. OPERA-02, a pivotal Phase 3 trial in combination with ribociclib in first-line disease, is supported by a collaboration and Supply agreement with Novartis announced in December 2024.

In October 2025 at the European Society for Medical Oncology meeting, the company presented updated results from the Phase 1b/2 trial of palazestrant with ribociclib, which it said support the first-line Phase 3 program. The company is also running Phase 1/2 combination studies with CDK4/6 inhibitors, a PI3K Alpha inhibitor, an mTOR inhibitor and a CDK4 inhibitor. Enrollment is complete in the study combining palazestrant with atirmociclib, and initial data from it, along with first clinical data from the everolimus combination, are scheduled for presentation at the San Antonio Breast Cancer Symposium in December 2026.

Dates and Figures to Follow

The December symposium data, the first quarter 2027 OPERA-01 readout and quarterly spending as two Phase 3 trials proceed are the dated items.